| 305 | 5 | 110 |
| 下载次数 | 被引频次 | 阅读次数 |
为研究中国水痘-带状疱疹病毒(Varicella Zoster Virus,VZV)gH(Glycoprotein H)、gK(Glycoprotein K)、gI(Glycoprotein I)糖蛋白基因特征,选取2007~2015年在中国六省收集的VZV疑似患者的疱疹液或咽拭子标本,经聚合酶链反应(Polymerase chain reaction,PCR)方法进行阳性鉴定及3个糖蛋白的全基因片段扩增,所得序列与GenBank中已公布的疫苗株及野毒株序列进行比对分析。结果筛选出12份阳性VZV标本,gH、gK、gI与水痘疫苗株核苷酸和氨基酸同源性相比分别为99.8%~100%、99.8%~100%,99.8%~100%、99.6%~100%,99.9%~100%、99.7%~100%;与疫苗株相比在gH、gK、gI糖蛋白基因位点上12份阳性标本分别至少有一个核苷酸差异;与GeneBank中已报告的野毒株相比核苷酸和氨基酸同源性分别为99.6%~100%、99.3%~100%,99.7%~100%、99.3%~100%,99.7%~100%、99.7%~100%。本研究通过分析中国六省VZV糖蛋白gH、gK、gI的基因特征,发现这三个糖蛋白高度保守,抗原性稳定,为了解中国水痘带状疱疹病毒野毒株糖蛋白本底资料,丰富基因数据,从分子水平上为疫苗效果的评估、基因组学的研究提供基础数据。但中国地域辽阔,人口众多,还需每年连续监测并进一步扩大VZV病毒监测的地域。
Abstract：We undertook genetic characterization of glycoprotein H(gH),glycoprotein K(gK),and glycoprotein I(gI)of the varicella zoster virus(VZV).Samples of vesicle fluid and throat swabs with suspected VZV were collected from individuals in six provinces of China from 2007 to 2015.Detection of positive samples and amplification of the three glycoprotein genes was by polymerase chain reaction(PCR).The results were analyzed with wild-type stains and vaccine strains of VZV-referenced sequences from GenBank.VZV-positive strains were detected in 12 samples.Compared with the vaccine strains,there was a nucleotide mutation in gH,gK and gI of wild-type strains.Simultaneously,there were four amino-acid mutations in gH and one amino-acid mutation in gK of wild-type strains.The homology of nucleotide sequences was 99.6%~100%、99.7%~100% and 99.8%~100%in gH,gK and gI respectively.The homology of the amino-acid sequence was 99.3%~100%,99.3%~100%and 99.7%~100%in gH,gK and gI,respectively.This study demonstrated that the genes of gH,gK and gI are highly conserved and remain stable as immunogens,which may be involved in VZV attenuation.
[1]Yawn B P,Saddier P,Wollan P C,St Sauver J L,Kurland M J,Sy L S.A population—based Study of the incidence and complication rates of herpes zostcr before zoster vaccine introduction[J].Mayo Clin Proc,2007,82(11):1341-1349.
[2]Quinlivan M and J Breuer,Clinical and molecular aspects of the live attenuated Oka varicella vaccine[J].Rev Med Virol,2014,24(4):254-273.
[3]Davison A J,Edson C M,Ellis R W,Forghani B,Gilden D,Grose C,Keller P M,Vafai A,Wroblewska Z,Yamanishi K.New common nomenclature for glycoproteins genes of Varicella-zoster virus and the glycosylated products[J].J Virol,1986,57(3):1195-1207.
[4]Olson J K,Grose C.Complex formation facilitates endocytosis of the varicella-zoster virus gE:gI Fc receptor[J].J Virol,1998,72(2):1542-1551.
[5]Mo C 1,Lee J,Sommer M,Grose C,Arvin A M.The requirement of varicella zoster virus glycoprotein E(gE)for viral replication and effects of glycoprotein I on gE in melanoma cells[J].Virology,2002,304(2):176-186.
[6]Committee oninfectious Disease,American academy of pediatrics.recommendation for the use of live attenuated varicella vaccine[J].Pediatrics,1995,95:791-796.
[7]Songtao Xu,Mukai Chen,Huanying Zheng,et al.Nationwide distribution of varicella-zoster virus clades in China[J].BMC Infectious Diseases,2016,16:542-548.
[8]Seward J F,Matin M,Vazquez M.Varicella vaccine effectiveness in the US vaccination program:A review[J].Infect Dis,2008,197(Suppl 2):S82-S89.
[9]张勇,赫宝双,赵海波.带状疱疹疫苗的研究现状及发展趋势[J].中国新药杂志,2012,21(10):1103-1106.
[10]Krause P R,Klinman D M.Varicella vaccination:evidence for f requent reactivation of the vaccine strain in healthy children[J].Nat Med,2000,6(4):451-454.
[11]La Russa P,Steinberg S P,Shapiro E,Vazquez M,Gershon A A.Viral strain identification in varicella vaccines with disseminated rashes[J].Pediatr Infect Dis J,2000,19(11):1037-1039.
[12]Shar rar R G,LaRussa P,Galea S A,Steinberg S P,Sweet A R,Keatley R M,Wells M E,Stephenson W P,Gershon A A.The postmarketing safety profile of varicella vaccine[J].Vaccine,2000,19(7-8):916-923.
[13]Gan L,Wang M,Yang S,Gershon A A,Chen J J.Transmission of varicella vaccine virus to a non-family member in China[J].Vaccine,2011,29(11):2015-2017.
[14]Leung J,Rue A,Lopez A,Ortega-Sanchez I R,Harpaz R,Guris D,Seward J F.Varicella outbreak reporting,response,management,and national surveilance[J].Infect Dis,2008,197(Suppl 2):S108-S113.
[15]Ogunjimi B,P Van Damme and P Beutels.Herpes Zoster Risk Reduction through Exposure to Chickenpox Patients:A Systematic Multi disciplinary Review[J/OL].PLoS One,2013,8(6):664-685.
[16]Silver B and H Zhu.Varicella zoster virus vaccines:potential complications and possible improvements[J].Virol Sin,2014,29(5):265-273.
[17]Kawai K,B G Gebremeskel and C J Acosta.Systematic review of incidence and complications of herpes zoster:towards a global perspective[J].BMJ Open,2014,4(6):483.
[18]Gomi Y,Sunamachi H,Mort Y,et a1.Comparison of the complete DNA sequences of the Oka varieella vaccine and its parentalvirus[J].J Virol,2002,76(22):11447-11459.
[19]Sato B,Ito H,Hinchliffe S,et a1.Mutational analysis of open reading frames 62and 71.encoding the varicellazoster virus immediate—early transactivating protein,IE62,and effects on replication in vitro and in skin xenografts in the SCID-hu mouse in vivo[J].J Virol,2003,77(10):5607-5620.
[20]Jong Ik Kim,Gyoo Seung Jung,Yu Young Kim,et a1.Sequencing and characterization of Varicella-zoster virus vaccine strain SuduVax.[J].Virology,2011,538-547.
[21]Santos R A,C C Hatfield,N L Cole,J A Padilla,J F Moffat,A M Arvin,W T Ruyechan,J Hay,and C Grose.Varicella-zoster virus gE escape mutant VZVMSP exhibits an accelerated cell-to-cell spread phenotype in both infected cell cultures and SCID-hu mice[J].Virology,2000,275:306-317.
[22]Grose C,S Tyler,G Peters,J Hiebert,G M Stephens,W T Ruyechan,W Jackson,J Storlie,and G A Tipples.Complete DNA sequence analyses of the first two varicella-zoster virus glycoprotein E(D150N)mutant viruses found in North America:evolution of genotypes with an accel-erated cell spread phenotype[J].J Virol,2004,78:6799-6807.
[23]Maresova L,T J Pasieka,and C Grose.Varicella-zoster Virus gB and gE coexpression,but not gB or gE alone,leads to abundant fusion and syncytium formation equivalent to those from gH and gL coexpression[J].J Virol,2001,75:9483-9492.
[24]Kinchington,P R,P Ling,M Pensiero,A Gershon,J Hay,and W T Ruyechan.A possible role for glycoprotein gpV in the pathogenesis of varicella-zoster virus[J].Adv Exp Med Bio,1990,278:83-91.
[25]Ling P,P R Kinchington,W T Ruyechan,and J.Hay.A detailed analysis of transcripts mapping to varicella zoster virus gene 14(glycoprotein V)[J].Virology,1991,184:625-635.
[26]Moffat,J.F,L.Zerboni,P.R Kinchington,C Grose,H.Kaneshima,and A M Arvin..Attenuation of the vaccine Oka strain of varicella-zoster virus and role of glycoprotein C in alphaherpesvirus virulence demonstrated in the SCID-hu mouse[J].J Virol,1998,72:965-974.
基本信息:
DOI：10.13242/j.cnki.bingduxuebao.003115
中图分类号:R373.1
引用信息:
[1]齐梦缘,吴秋华,杨玉颖,等.中国六省水痘-带状疱疹病毒糖蛋白基因特征分析[J].病毒学报,2017,33(02):156-162.DOI:10.13242/j.cnki.bingduxuebao.003115.
基金信息:
国家自然科学基金(项目号:81302477),题目:水痘-带状疱疹病毒基因型在我国的分布及糖蛋白基因特征研究; 国家重点研发计划课题(项目号:2016YFC1200905),题目:重要新发突发病原体应急处置方案与规范研究
2017-03-29
2017-03-29
2017-03-29